Financial Commitments & Contingencies and Key License Agreements - Additional Information (Details)				1 Months Ended		12 Months Ended
	Jan. 01, 2022 USD ($)	Aug. 31, 2021 plaintiff	May 28, 2021 patent	Dec. 31, 2020 USD ($)	Apr. 30, 2018 USD ($)	Dec. 31, 2021 USD ($) licensor	Dec. 31, 2020 USD ($)
Long-term Purchase Commitment [Line Items]
Right-of-use assets in exchange for lease liabilities						$ 1,800,000	$ 0
Facility and equipment under lease				$ 2,247,000		$ 2,505,000	2,247,000
Licensors | licensor						2
Deferred compensation liability, current and noncurrent				9,800,000		$ 11,200,000	9,800,000
Bioverativ Therapeutics Inc., Subject Patents
Long-term Purchase Commitment [Line Items]
Patents allegedly infringed | patent			3
Therapyx | In-License Agreement with Therapyx
Long-term Purchase Commitment [Line Items]
Asset purchase agreement, upfront payment				800,000
Potential payments based on worldwide annual net sales				167,500,000
Therapyx | In-License Agreement with Therapyx | Acceptance of certain transferred materials
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones				2,200,000
Therapyx | In-License Agreement with Therapyx | First approved IL-12 product
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones				30,000,000
Therapyx | In-License Agreement with Therapyx | Each new indication approved for each product in the U.S., Europe, or Japan
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones				2,500,000
Hanmi | Eflapegrastim: Co-Development and Commercialization Agreement with Hanmi
Long-term Purchase Commitment [Line Items]
Potential payments based on additional achievements of regulatory milestones					$ 10,000,000
Hanmi | Poziotinib: In-License Agreement with Hanmi and Exclusive Patent and Technology License Agreement with MD Anderson | Subsequent Event
Long-term Purchase Commitment [Line Items]
Achievement of regulatory milestones potential payments	$ 18,000,000
Supplemental royalty milestone limit	$ 15,000,000
MD Anderson
Long-term Purchase Commitment [Line Items]
Achievement of regulatory milestones potential payments					6,000,000
Payment of upfront fee					500,000
Potential payments based on achievement of sales milestones					$ 24,000,000
Plaintiffs, Individuals | Shareholder Litigation
Long-term Purchase Commitment [Line Items]
Number of plaintiffs | plaintiff		4
Plaintiff, Entity | Shareholder Litigation
Long-term Purchase Commitment [Line Items]
Number of plaintiffs | plaintiff		1
Office and research facilities
Long-term Purchase Commitment [Line Items]
Facility and equipment under lease				1,900,000		2,100,000	1,900,000
Office equipment
Long-term Purchase Commitment [Line Items]
Facility and equipment under lease				$ 300,000		$ 400,000	$ 300,000
Minimum
Long-term Purchase Commitment [Line Items]
Remaining term						1 year
Maximum
Long-term Purchase Commitment [Line Items]
Remaining term						5 years